Paper22992140
Immune modulation in Pompe disease treated with enzyme replacement therapy.
Banugaria SG and 2 others. Expert Rev Clin Immunol, 2012. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Immune modulation in Pompe disease treated with enzyme replacement therapy. Papers, record 22992140. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22992140
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Enzyme Replacement Therapy | Major topic |
| Glycogen Storage Disease Type II | Major topic |
| Immunomodulation | Major topic |
| alpha-Glucosidases | Major topic |
| Animals | |
| Antibodies | |
| Humans | |
| Mice |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40123743 | Antibodies to recombinant human alpha-L-iduronidase prevent disease correction in cortical bone in MPS I mice. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/40123743 | PubMed |
| 39604266 | A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease. | Mol Ther | 2025 | https://conductscience.org/library/papers/39604266 | PubMed |
| 35248118 | Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel. | Ital J Pediatr | 2022 | https://conductscience.org/library/papers/35248118 | PubMed |
| 29649469 | Phosphatidylserine Is Not Just a Cleanup Crew but Also a Well-Meaning Teacher. | J Pharm Sci | 2018 | https://conductscience.org/library/papers/29649469 | PubMed |
| 28874182 | Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. | Acta Neuropathol Commun | 2017 | https://conductscience.org/library/papers/28874182 | PubMed |
| 28648664 | High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient. | Mol Genet Metab | 2017 | https://conductscience.org/library/papers/28648664 | PubMed |
| 27896120 | Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. | Mol Genet Metab Rep | 2014 | https://conductscience.org/library/papers/27896120 | PubMed |
| 27747161 | Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV. | Mol Genet Metab Rep | 2016 | https://conductscience.org/library/papers/27747161 | PubMed |
| 27493997 | Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses. | JCI Insight | 2016 | https://conductscience.org/library/papers/27493997 | PubMed |
| 27488899 | Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease. | J Pharm Sci | 2016 | https://conductscience.org/library/papers/27488899 | PubMed |
| 26883220 | The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders. | J Inherit Metab Dis | 2016 | https://conductscience.org/library/papers/26883220 | PubMed |
| 25881001 | Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders. | Mol Ther | 2015 | https://conductscience.org/library/papers/25881001 | PubMed |
| 25548186 | Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. | Proc Natl Acad Sci U S A | 2015 | https://conductscience.org/library/papers/25548186 | PubMed |
| 24176423 | Clinical neurogenetics: neuropathic lysosomal storage disorders. | Neurol Clin | 2013 | https://conductscience.org/library/papers/24176423 | PubMed |
| 23825616 | Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. | PLoS One | 2013 | https://conductscience.org/library/papers/23825616 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22992140
GET https://conductscience.org/api/papers/v1/22992140/authors